• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Is There a Case for Cannabis in the Treatment of Pain?

Is There a Case for Cannabis in the Treatment of Pain?

August 30, 2019
Adrienne Grzenda, MD, PhD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adrienne Grzenda, MD, PhD. Dr. Grzenda has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Da Vita et al, JAMA Psychiatry 2018;75(11):1118-1127

Study Type: Meta-analysis of placebo-controlled trials

In the midst of the opioid epidemic, researchers are looking for new ways to treat chronic pain. Interestingly, states that have legalized medical marijuana have fewer opioid prescriptions but no clear reduction in mortality over time (Shover CL et al, Proc Natl Acad Sci U S A. 2019;116(26):12624-12626). Opioid users who smoke marijuana are less likely to drop out of maintenance treatment programs, while benzodiazepine use predicts worse outcomes in this population (Powell et al, J Health Econ 2018:58:29-42; Socías ME et al, Addiction 2018;113:2250-2258). Could marijuana have direct benefits in the treatment of pain?

To address this question, researchers analyzed 18 placebo-controlled trials of cannabinoids as a treatment for mechanically-induced pain in otherwise healthy subjects. A total of 442 participants were included. Mean age was 27 with equal numbers of men and women. Two-thirds of the studies involved synthetic tetrahydrocannabinol (THC), the cannabinoid responsible for the “high” in marijuana, or schedule-III analogues of THC, such as dronabinol and nabilone. The other third used plant-based cannabis. The majority (89%) used a cross-over design where subjects received both cannabinoids and placebo with a washout period between the doses.

Compared to placebo, cannabinoid administration was associated with a small increase in pain threshold and a small-to-medium increase in pain tolerance. However, it did not change overall pain intensity. Cannabinoids made people better able to withstand a greater pain burden, but only to a certain point. They also made the experience of pain less unpleasant (small-to-medium effect size), and this effect was strongest with plant-based cannabis. Unpleasantness is important because it may influence the progression from chronic pain to depression. No significant association was found between cannabinoid administration and hypersensitivity to pain. Gender did not significantly impact any of the outcomes.

The biggest limitation to the study is the lack of blinding as most subjects could probably guess whether or not they were “high.” Furthermore, it is unclear how well mechanically induced pain approximates real, chronic pain. Lastly, cannabidiol (CBD) was not included in the study. CBD is often praised by enthusiasts for its properties and was recently approved in a prescription form for intractable seizures (Epidiolex; see TCPR Jan 2019). Unlike THC, CBD produces no “high” and may have added antipsychotic effects.

TCPR’S TAKE
Despite the widespread use of THC for a variety of ailments, little data exist to support its many claimed benefits. Additionally, the risks, including psychosis, are too large to recommend it to patients as an alternative analgesic.
General Psychiatry
KEYWORDS cannabidiol cannabis marijuana opioids pain research research-update
Adrienne Grzenda, MD, PhD.

Who's Who? A Review of Delusional Misidentification Syndromes

More from this author
www.thecarlatreport.com
Issue Date: August 30, 2019
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - How to Talk about Medication, TCPR, September 2019
Is There a Case for Cannabis in the Treatment of Pain?
Is Paxil the Best SSRI for Anxiety?
A New Contraindication for Ambien and the Z-Hypnotics
A New Way to Talk to Patients about Medication
Mirtazapine Augmentation: Running Low on Rocket Fuel
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.